May 1, 2024 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.01 EPS, expectations were $-0.0075.

Finally, we secured shareholder approval for our share repurchase program, and we expect share repurchases to begin following UK High Court approval in the second quarter,” said Patrick Holt, ...

Goldman Sachs analyst Paul Choi maintained a Sell rating on Amarin (AMRN – Research Report) today and set a price target of $1.00. Paul ...

Be aware that Amarin is showing 1 warning sign in our investment analysis that you should know about... Have feedback on this ...

DUBLIN — DUBLIN — Amarin Corp. PLC (AMRN) on Wednesday reported a loss of $10 million in its first quarter. The Dublin-based company said it had a loss of 2 cents per share. Losses, adjusted for stock ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Amarin's Vazkepa notched a crucial win with a European regulator. The medication earned an extension to its patent exclusivity on that market. You’re reading a free article with opinions that ...

Warning! GuruFocus has detected 3 Warning Signs with AMRN. Amarin Corp PLC (NASDAQ:AMRN) disclosed its financial outcomes for ...

Amarin is going through a turbulent period with a strong contraction in revenue and margins. The EU and China markets seem too small to make significant changes, and the US market is suffering ...

Good day, and welcome to Amarin Corporation's conference call to discuss its first quarter 2024 financial results and ...

That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about its single commercialized drug that day. As a result, its shares were trading more than 6% higher ...